Stock 000963 HUADONG MEDICINE CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Huadong Medicine Co., Ltd Stock

Equities

000963

CNE0000011S1

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
31.37 CNY -1.78% Intraday chart for Huadong Medicine Co., Ltd -0.88% -24.34%
Jun. 06 Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic RE
Jun. 06 Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China RE

Financials

Sales 2024 * 45.03B 6.21B Sales 2025 * 49.11B 6.77B Capitalization 54.9B 7.57B
Net income 2024 * 3.31B 456M Net income 2025 * 3.95B 545M EV / Sales 2024 * 1.13 x
Net cash position 2024 * 3.88B 535M Net cash position 2025 * 5.76B 794M EV / Sales 2025 * 1 x
P/E ratio 2024 *
16.6 x
P/E ratio 2025 *
13.9 x
Employees 16,969
Yield 2024 *
1.53%
Yield 2025 *
1.78%
Free-Float 41.92%
More Fundamentals * Assessed data

Chart Huadong Medicine Co., Ltd

Dynamic Chart

Latest news about Huadong Medicine Co., Ltd

Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic RE
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China RE
Huadong Medicine Gets Regulatory OK to Test Tumor Drug MT
Huadong Medicine Co., Ltd Approves Cash Dividend for the Year 2023 CI
Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Huadong Medicine's 2023 Profit Jumps 14% MT
Huadong Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China's first biosimilar Ozempic drug applies for approval RE
Huadong Medicine to Build 2 Billion Yuan Biopharma Innovation Center MT
Huadong Medicine to Invest 2 Billion Yuan in Biopharma Innovation Center MT
Huadong Medicine's 2023 Profit to Climb Up to 14.5% MT
Huadong Medicine Eyes Exclusive Marketing Rights for Cancer Drug Senaparib in China for 290 Million Yuan MT
Huadong Medicine's Unit Gains Chinese Drug Regulator's Nod to Trial Sirolimus Oral Solution MT
Chongqing Yuyan Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in funding from Huadong Medicine Co., Ltd, Hangzhou State Capital Investment And Operations Co., Ltd., Hangzhou Gongshu State Investment Industry Development Co., Ltd. CI
Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm CI
More news

Press releases Huadong Medicine Co., Ltd

MC2 Therapeutics and Huadong Announce License, Development and Commercialization Agreement for Wynzora Cream in Greater China AQ
CARsgen Announced 2023 Interim Results AQ
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia AQ
CARsgen Announced 2022 Annual Results and Business Updates AQ
Ad hoc announcement inside information pursuant to Article 17 MAR Heidelberg Pharma AG Announces Adjustment of Guidance AQ
More press releases

News in other languages on Huadong Medicine Co., Ltd

El primer medicamento chino bioequivalente a Ozempic solicita su aprobación
Weniger chinesische Übernahmen in Deutschland und Europa - Studie
More news

Quotes and Performance

1 day-1.78%
1 week-0.88%
Current month-0.82%
1 month-6.11%
3 months-2.09%
6 months-20.60%
Current year-24.34%
More quotes

Highs and lows

1 week
31.30
Extreme 31.3
32.69
1 month
30.82
Extreme 30.82
34.68
Current year
27.60
Extreme 27.6
41.45
1 year
27.60
Extreme 27.6
46.43
3 years
27.60
Extreme 27.6
51.91
5 years
16.02
Extreme 16.02
53.94
10 years
13.57
Extreme 13.5694
53.94
More quotes

Managers and Directors - Huadong Medicine Co., Ltd

Managers TitleAgeSince
Hong Lan Ma DFI
 Director of Finance/CFO 53 -
Bang Liang Li CHM
 Chairman 78 71-12-31
Dong Zhou Liu CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Cheng Wei Liu BRD
 Director/Board Member 50 02-12-31
Liang Lü CEO
 Chief Executive Officer 50 10-03-31
Xin Hua Bai CHM
 Chairman 58 02-12-31
More insiders

ETFs positioned on Huadong Medicine Co., Ltd

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
1.41% 1 M€ -18.21% -
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.99% 2 M€ -14.14%
More ETFs positioned on Huadong Medicine Co., Ltd

Quotes

Date Price Change Volume
24-06-07 31.37 -1.78% 7,009,593
24-06-06 31.94 -0.84% 8,008,900
24-06-05 32.21 -0.77% 6,670,502
24-06-04 32.46 +2.56% 12,736,180

End-of-day quote Shenzhen S.E., June 06, 2024

More quotes

Company Profile

Huadong Medicine Co., Ltd. specializes in the development, manufacture and marketing of medical products and vaccines. The products are intended primarily for the treatment of tumors, immune disorders, endocrine disorders, orthopedic and traumatological disorders, digestive system diseases and viral diseases.
Sector
Pharmaceuticals
Calendar
2024-06-18 - Extraordinary Shareholders Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Huadong Medicine Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
31.37 CNY
Average target price
44.11 CNY
Spread / Average Target
+40.61%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-24.34% 7.58B
MCKESSON CORPORATION Stock McKesson Corporation
+27.71% 76.29B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-1.94% 23.99B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+8.07% 9.01B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+12.25% 8.67B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+12.94% 5.18B
GALENICA AG Stock Galenica AG
+1.99% 4.16B
EBOS GROUP LIMITED Stock EBOS Group Limited
-7.75% 3.98B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
-1.36% 3.63B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+20.13% 3.58B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 000963 Stock